NeoRich BioPharma Tech Co., Limited
PHBID
$0.45
-$0.43-49.28%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -33.33% | -64.29% | 0.00% | 10.00% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -33.33% | -64.29% | 0.00% | 10.00% | -- |
| Cost of Revenue | 0.00% | -42.86% | 25.00% | -70.00% | -- |
| Gross Profit | -50.00% | -85.71% | -50.00% | -- | -- |
| SG&A Expenses | -18.68% | -44.75% | -27.32% | -45.24% | -58.67% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -18.56% | -44.73% | -26.96% | -45.37% | -58.40% |
| Operating Income | 18.35% | 44.43% | 27.17% | 45.87% | 59.11% |
| Income Before Tax | 537.06% | -336.47% | 73.85% | 79.79% | -267.77% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 537.06% | -336.47% | 73.85% | 79.79% | -267.77% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 537.06% | -336.47% | 73.91% | 79.79% | -267.77% |
| EBIT | 18.35% | 44.43% | 27.17% | 45.87% | 59.11% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 526.00% | -233.62% | 82.50% | 86.16% | -153.97% |
| Normalized Basic EPS | 519.41% | -205.75% | 83.13% | 86.16% | -158.08% |
| EPS Diluted | 526.00% | -233.62% | 82.50% | 86.16% | -153.97% |
| Normalized Diluted EPS | 519.41% | -205.75% | 83.13% | 86.16% | -158.08% |
| Average Basic Shares Outstanding | 2.63% | 30.78% | 49.12% | 45.91% | 44.78% |
| Average Diluted Shares Outstanding | 2.63% | 30.78% | 49.12% | 45.91% | 44.78% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |